Wavre

Human papillomavirus (HPV) infection is very common and often causes warts in people of all ages. This study evaluates the effectiveness of 2LVERU4 JUNIOR and 2LVERU4 treatments compared to a placebo in helping warts disappear. The trial aims to compare how well these treatments work by the end of a 6-month period, focusing on common, flat, and plantar warts caused by HPV. It is a phase 4, randomized, placebo-controlled, double-blind study involving patients aged 3 years and older. Participants will be assigned to one of two groups: one receiving 2LVERU4 JUNIOR or 2LVERU4 capsules, and the other receiving placebo capsules. Each participant will take one capsule daily, 15 to 30 minutes before breakfast on an empty stomach, following a sequence of capsules numbered 1 through 10, repeated continuously for 6 months. After the treatment phase, there is a 3-month follow-up period to monitor results and any possible recurrence of warts. During the study, patients will be monitored for wart disappearance, defined by normal skin color, texture, and touch at the wart site. Assessments will take place at 4 and 6 months after starting treatment, with additional evaluation of wart recurrence 3 months after treatment ends. Researchers will also compare pain levels related to warts and monitor safety throughout the study. The total study duration can last up to 45 months, including 36 months for patient enrollment and 9 months for follow-up.

Epstein-Barr Virus (EBV) infects about 95% of adults worldwide and can cause various diseases, including infectious mononucleosis and chronic fatigue syndrome. Usually, the infection shows no symptoms due to an effective immune response. Currently, there is no treatment that eliminates EBV, and care focuses on managing symptoms such as pain. This study aims to evaluate the effectiveness of two drugs, 2LEBVAE and 2LXFSAE, compared to a placebo in reducing fatigue and other symptoms in patients with EBV infections. Participants will receive either 2LEBVAE, 2LXFSAE, or a placebo, following the same treatment schedule. Each day, they will take one capsule on an empty stomach, 15 to 30 minutes before breakfast, in numerical order from capsule 1 through 10. After finishing capsule 10, they continue with capsule 1 of the next blister pack. This daily treatment will continue for 6 months without interruption. During the study, participants will be evaluated using the Multidimensional Fatigue Inventory-20 questionnaire to measure general fatigue at the end of the 6-month treatment. Researchers will monitor symptoms and treatment adherence throughout the study. The goal is to gather additional information on the effectiveness of these drugs in treating acute and chronic EBV infections and improving patient fatigue and other related symptoms.